These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 36568203)

  • 1. Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials.
    Zheng J; Huang B; Xiao L; Wu M; Li J
    Front Oncol; 2022; 12():821626. PubMed ID: 36568203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.
    Gu J; Shi L; Jiang X; Wen J; Zheng X; Cai H; Zhang W
    Cancer Immunol Immunother; 2022 Sep; 71(9):2239-2254. PubMed ID: 35124713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
    Zhang W; Gu J; Bian C; Huang G
    Front Pharmacol; 2021; 12():686876. PubMed ID: 34759817
    [No Abstract]   [Full Text] [Related]  

  • 4. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis.
    Wang S; Yan L; Yu J; Lu C
    Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3385-3395. PubMed ID: 38358507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis.
    Liu T; Jin B; Chen J; Wang H; Lin S; Dang J; Li G
    Ther Adv Med Oncol; 2020; 12():1758835920940927. PubMed ID: 32774474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
    Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
    BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
    Liang X; Xiao H; Li H; Chen X; Li Y
    Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis.
    Mei T; Wang T; Deng Q; Gong Y
    Front Immunol; 2023; 14():1062679. PubMed ID: 36825025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
    Wang S; Lv H; Yu J; Chen M
    Int Immunopharmacol; 2024 Apr; 131():111884. PubMed ID: 38518592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
    Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
    JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Huang D; Sun F; Ke L; Li S
    Int Immunopharmacol; 2024 Sep; 138():112576. PubMed ID: 38941672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.
    Mao YT; Wang Y; Chen XX; Liu CJ; Bao Q
    J Cosmet Dermatol; 2024 Apr; 23(4):1165-1177. PubMed ID: 38013634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of treatment-related adverse events of immunotherapy in advanced gastric or gastroesophageal junction cancer: A meta-analysis of randomized controlled trials.
    Yuan H; Duan DD; Zhang YJ
    Clin Res Hepatol Gastroenterol; 2022 Dec; 46(10):102031. PubMed ID: 36261109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Da L; Teng Y; Wang N; Zaguirre K; Liu Y; Qi Y; Song F
    Front Pharmacol; 2019; 10():1671. PubMed ID: 32082164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a meta-analysis based on mixed-effect models.
    Zheng J; Deng Y; Huang B; Chen X
    Front Med (Lausanne); 2023; 10():1198950. PubMed ID: 37583422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.